SAB Biotherapeutics Inc (SABS)
4.03
+0.01
(+0.25%)
USD |
NASDAQ |
May 03, 16:00
SAB Biotherapeutics Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2023 | 0.0404 |
| December 31, 2022 | 0.0423 |
| September 30, 2022 | 0.0008 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.0007 |
| March 31, 2022 | 0.0006 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0006
Minimum
Mar 2022
0.0423
Maximum
Dec 2022
0.017
Average
0.0008
Median
Sep 2022
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.00 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 0.3431 |
| Protalix BioTherapeutics Inc | 0.6033 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 83.94M |
| Total Liabilities (Quarterly) | 26.64M |
| Shareholders Equity (Quarterly) | 57.30M |